Session information

Symposium

[S06] How can we change medicine by radiation and pharmaceuticals?

Sun. Mar 26, 2023 10:10 AM - 12:10 PM [Room M2] The Alumni Hall "Frate": Seminar Room (1F)

Organizer: Kazuma Ogawa, Hiroyuki Kimura

Radiopharmaceuticals are essential for diagnosis and therapy in nuclear medicine. With the approval of a drug for peptide receptor radionuclide therapy (¹⁷⁷Lu-DOTATATE: Lutathera®) in Japan in 2021, therapy in nuclear medicine has been attracting a great deal of attention in recent years. As a result, the development of therapeutic radiopharmaceuticals has entered a new phase. In addition, developing many types of radiopharmaceuticals, such as small molecules, peptides, antibodies, and nanoparticles, is promoted. On the other hand, boron neutron capture therapy (BNCT), approved in 2020, is a cancer treatment method using Li nuclei and alpha particles generated by in vivo nuclear reaction to boron (¹⁰B) drugs accumulated in cancer by neutron irradiation. Naturally, BNCT needs drugs with ¹⁰B. Common to both therapies are "radiation and drugs," and great expectations are placed on pharmaceutical sciences, especially about drugs. In this symposium, we would like to discuss this field's current status and future prospects by inviting researchers conducting cutting-edge research in their respective fields as speakers.

+Add all to schedule

オーガナイザー挨拶・趣旨説明：木村寛之（京都薬大） (10:10 AM - 10:15 AM)

10:15 AM - 10:37 AM

[S06-01] Current status and future perspectives of radionuclide therapy with ¹⁷⁷Lu

○Hiroyuki Kimura¹ (1. Kyoto Pharm. Univ.)

10:37 AM - 10:59 AM

[S06-02] Trial for alpha therapy by fusion of organic chemistry, medicinal science, and nuclear chemistry

○Shino Manabe^1,2, Hiroki Takashima³, Hiromitsu Haba⁴, Masahiro Yasunaga³, Hirofumi Fujii³ (1. Hoshi University, 2. Tohoku University, 3. National Cancer Center, 4. RIKEN)

10:59 AM - 11:21 AM

[S06-03] Current status and issues of boron neutron capture therapy based on real world clinical data

○Katsumi Hirose^1,2 (1. Southern Tohoku BNCT Research Center, 2. Hirosaki Univ. Grad. Sch. Med.)

11:21 AM - 11:43 AM

[S06-04] Development of Radiopharmaceuticals for Cu-64 treatment

○Yukie Yoshii¹ (1. QST)

11:43 AM - 12:05 PM

[S06-05] Targeted Alpha Therapy (TAT): Present and Future

○Kazuma Ogawa^1,2 (1. InFiniti, Kanazawa Univ., 2. Grad. Sch. Pharm. Kanazawa Univ.)

総括：小川数馬^1,2（¹金沢大新学術，²金沢大院薬） (12:05 PM - 12:10 PM)

Authentication

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.

Please log in with your participant account.
» Participant Log In

▲